Bhattacharyya, Sudeepa http://orcid.org/0000-0003-3493-6029
Ahmed, Ahmed T.
Arnold, Matthias http://orcid.org/0000-0002-4666-0923
Liu, Duan http://orcid.org/0000-0003-1065-246X
Luo, Chunqiao
Zhu, Hongjie
Mahmoudiandehkordi, Siamak
Neavin, Drew
Louie, Gregory http://orcid.org/0000-0002-3267-7070
Dunlop, Boadie W.
Frye, Mark A.
Wang, Liewei
Weinshilboum, Richard M.
Krishnan, Ranga R.
Rush, A. John
Kaddurah-Daouk, Rima http://orcid.org/0000-0003-1858-5732
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH108348, R01MH108348, R01MH108348, R01MH108348, R01MH108348)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008685)
U.S. Department of Health & Human Services | National Institutes of Health (T32 GM072474)
Article History
Received: 5 September 2018
Revised: 29 March 2019
Accepted: 29 April 2019
First Online: 4 July 2019
Conflict of interest
: R.M.W. is a cofounder and stockholder in OneOme, LLC, a pharmacogenomic clinical decision support company. A.J.R. has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC., Emmes Corp., Johnson and Johnson (Janssen), Liva-Nova, Mind Linc, Sunovion, and Taj Medical; speaking fees from Liva-Nova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named the coinventor on two patents: US Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication and US Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events during Treatment with Antidepressant Medication. M.A.F. has received grant support from AssureRx Health Inc, Myriad, Pfizer Inc, NIMH (R01 MH079261), the National Institute on Alcohol Abuse and Alcoholism (P20AA017830) in the National Institutes of Health at the US Department of Health and Human Services, and the Mayo Foundation. He has been a consultant (for Mayo) to Janssen Global Services, LLC; Mitsubishi Tanabe Pharma Corp; Myriad Genetics, Inc; Sunovion Pharmaceuticals, Inc; and Teva Pharmaceutical Industries Ltd. He has received continuing medical education, travel, and presentation support from the American Physician Institute and CME Outfitters. L.W. was supported by NIH grants U19 GM61388, U54 GM114838, and NSF164615. She is a cofounder and stockholder in OneOme. R.K.-D. is an inventor on key patents in the field of metabolomics. D.N.’s stipend has been supported in part by NIH T32 GM072474 and the Mayo Graduate School. A.T.A.’s research was supported by National Institute of General Medical Sciences of the National Institutes of Health under award number T32 GM008685. M.A. was supported by the National Institute on Aging [R01AG057452, RF1AG051550, and R01AG046171], National Institute of Mental Health [R01MH108348], and Qatar National Research Fund [NPRP8-061-3-011]. The funders listed above had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the paper; and decision to submit the manuscript for publication.